<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04235673</url>
  </required_header>
  <id_info>
    <org_study_id>20180004210 17/01/2018</org_study_id>
    <nct_id>NCT04235673</nct_id>
  </id_info>
  <brief_title>Oral Melatonin as Neuroprotectant in Preterm Infants</brief_title>
  <official_title>Oral Melatonin as Neuroprotectant in Preterm Infants .A Prospective, Double Blind vs Placebo, Parallel Arms Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Francesca Garofoli</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>IRCCS National Neurological Institute &quot;C. Mondino&quot; Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pavia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>IRCCS Policlinico S. Matteo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Preterm newborns survival rates are improved, but long-term disabilities are still common.
      Major destructive focal lesions became less common, the most predominant lesion at present is
      diffuse white matter (WM damage). Melatonin (ME) serves as a neuroprotectant cerebral
      ischemia through its potent anti-oxidant/-inflammatory effect. Preclinical studies
      demonstrated that protects the developing brain by preventing abnormal myelination and
      inflammatory glial reaction. Clinical studies demonstrated ME ability in reducing brain
      damage after neonatal Hypoxic Ischemic Encephalopathy (HIE) or preventing neonatal
      impairments due to antenatal/ post-natal injuries: preeclampsia,
      IntraUterineGrowthRestriction (IUGR), ventilation, Bronchopulmonary Dysplasia (BPD). ME has a
      good safety profile with no known adverse effects. This study aims to highlight that ME can
      prevent brain impairment due to premature birth. ME will be administered orally (3 mg/kg/die
      for 15 days to neonates born before 29+6 week gestation, in a prospective double blind,
      randomized vs placebo study, 2 parallel arms. ME and malondialdehyde (MDA), a lipid
      peroxidation product) levels before and at the end of treatment will be measured . Other
      outcomes: Cerebral ultrasounds (cUS); cerebral magnetic resonance imaging (cMRI), &quot; Fagan
      test &quot; eye tracking, ophthalmological, auditory, neurological/cognitive child assessments.
      Monitoring parental distress, which can influence the neurodevelopmental outcome in preterms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      About 552.000 infants are born in Italy each year, 1% of them with gestational age under 30
      weeks. Survival rates are improved, but long-term disabilities are still common. Major
      destructive focal lesions became less common, the most predominant lesion at present is
      diffuse white matter (WM damage). The prevention of neurodevelopmental impairment is a major
      public health challenge and efforts are needed to test neuroprotective strategies. Melatonin
      (ME) serves as a neuroprotectant cerebral ischemia through its potent
      anti-oxidant/-inflammatory effect. Preclinical studies demonstrated that protects the
      developing brain by preventing abnormal myelination and inflammatory glial reaction. Clinical
      studies demonstrated ME ability in reducing brain damage after neonatal Hypoxic Ischemic
      Encephalopathy (HIE) or preventing neonatal impairments due to antenatal/ post-natal
      injuries: preeclampsia, IntraUterineGrowthRestriction (IUGR), ventilation, Bronchopulmonary
      Dysplasia (BPD). Ongoing studies are testing in premature neonates and pregnant women its
      neuroprotective properties. ME has a good safety profile with no known adverse effects.

      This study aims to highlight that ME can prevent brain impairment due to premature birth. ME
      will be administered orally (3 mg/kg/die for 15 days within 96 hours from birth) to neonates
      born before 29+6 week gestation age (GA), in a prospective double blind, randomized vs
      placebo study, 2 parallel arms (30 preterm infants each). ME and malondialdehyde (MDA, a
      lipid peroxidation product) levels will be measured before and at the end of treatment. At
      birth, within 40 weeks of neonatal age, at 4-6 and at 24 months of age the following
      examinations are performed: Cerebral ultrasounds (cUS); cerebral magnetic resonance imaging
      (cMRI), during natural sleep (i.e. adopting sleep deprivation and/or feeding protocols);
      &quot;Fagan test&quot;eye tracking, ophthalmological, auditory brain stem evoked response (ABR),
      neurological/cognitive child assessments. Monitoring parental distress, which can influence
      the neurodevelopmental outcome in preterms.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2020</start_date>
  <completion_date type="Anticipated">September 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Malondialdehyde</measure>
    <time_frame>15 days</time_frame>
    <description>plasmatic concentration pg/ml</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Melatonin</measure>
    <time_frame>15 days</time_frame>
    <description>plasmatic concentration pg/ml</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cranial ultrasound (cUS) Assessment</measure>
    <time_frame>up to 40 weeks</time_frame>
    <description>to identify and score White Matter injuries</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain Magnetic Resonance Immaging (cMRI) Assessment</measure>
    <time_frame>up to 40 weeks</time_frame>
    <description>Identify and score White Matter injuries</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Auditory brain stem evoked response (ABR) Assessments</measure>
    <time_frame>up to 40 weeks</time_frame>
    <description>Identify and score auditory diseases</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Fagan Test of Infant Intelligence (FTII)</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Measure the time ( minutes) to recognize unfamiliar versus familiar human faces to gauge visual-spatial encoding, attention, and working memory in infants.</description>
  </other_outcome>
  <other_outcome>
    <measure>Griffiths Mental Developmental Scales'Revised (GMDS-R)</measure>
    <time_frame>up to 24 months</time_frame>
    <description>The scales rate infant development across 5 main areas (locomotor, personal and social skills, hearing and language, eye and hand co-ordination, and performance), providing a general developmental quotient (DQ) of infants' abilities and 5 subscale quotients (SQ).</description>
  </other_outcome>
  <other_outcome>
    <measure>Child Behavior Checklist (CBCL) scales.</measure>
    <time_frame>up to 24 months</time_frame>
    <description>A self-rating scale to evaluate emotional, social, and behavioral problems in infants, according to the parents' evaluation.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Malondialdehyde</condition>
  <condition>Melatonin</condition>
  <arm_group>
    <arm_group_label>melatonin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>melatonin oral drops; 3 mg/kg/day for 15 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>oral drops manufactured to mimic melatonin</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>melatonin</intervention_name>
    <description>orally administered drops</description>
    <arm_group_label>melatonin</arm_group_label>
    <other_name>not reported</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>orally administered drops</description>
    <arm_group_label>placebo</arm_group_label>
    <other_name>not reported</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  preterm newborns gestational age GA &lt; 29+6 weeks + day

          -  able to receive min 20ml/kg/day enteral nutrition, within 96 hours from birth

          -  written informed consent by both the parents.

        Exclusion Criteria:

          -  preterm newborns GA &gt; 29+6 weeks + days

          -  not able to receive enteral nutrition (min 20 ml/kg/die) within 96 hours of life

          -  infants with genetic and/or congenital metabolic or chronic diseases

          -  intraventricular hemorrhage (IVH) ≥ III,

          -  parents refusing to sign a written informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Weeks</minimum_age>
    <maximum_age>30 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chryssoula Tzialla, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRCCS Policlinico S. Matteo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chryssoula Tzialla, MD</last_name>
    <phone>+39 0382 502604</phone>
    <email>c.tzialla@smatteo.pv.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Francesca Garofoli, PhD</last_name>
    <phone>+39 0382 502865</phone>
    <email>lab.immunoneo@smatteo.pv.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fondazione IRCCS Mondino</name>
      <address>
        <city>Pavia</city>
        <state>PV</state>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Simona Orcesi, MD</last_name>
      <phone>+39 0382 3801</phone>
      <email>simona.orcesi@mondino.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Neonatal Unit and NICU, IRCCS Policlinico S. Matteo.</name>
      <address>
        <city>Pavia</city>
        <state>PV</state>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Chryssoula Tzialla, MD</last_name>
      <phone>+39 0382 502604</phone>
      <email>c.tzialla@smatteo.pv.it</email>
    </contact>
    <contact_backup>
      <last_name>Stefania Longo, MD</last_name>
      <phone>+39 0382 502704</phone>
      <email>s.longo@smatteo.pv.it</email>
    </contact_backup>
    <investigator>
      <last_name>Chryssoula Tzialla, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stefania Longo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francesca Garofoli, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elisa Civardi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Beatrice Grenci, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Simona Zanette, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Micol Angelini, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Camilla Pisoni, PsyD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lina Bollani, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Federico Zappoli Thyrion, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anna Simoncelli</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giada Gola,</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elvis Lafe</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giuseppina Sanfilippo</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vittoria Rizzo</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Università di Pavia</name>
      <address>
        <city>Pavia</city>
        <state>PV</state>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Iolanda Mazzucchelli, PhD</last_name>
      <phone>+39 0383 986372</phone>
      <email>iolanda.mazzucchelli@unipv.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>May 23, 2019</study_first_submitted>
  <study_first_submitted_qc>January 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2020</study_first_posted>
  <last_update_submitted>January 16, 2020</last_update_submitted>
  <last_update_submitted_qc>January 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS Policlinico S. Matteo</investigator_affiliation>
    <investigator_full_name>Francesca Garofoli</investigator_full_name>
    <investigator_title>PhD, Researcher, Co-PI,</investigator_title>
  </responsible_party>
  <keyword>Preterm neonate</keyword>
  <keyword>Neuroprotection</keyword>
  <keyword>Malondialdehyde</keyword>
  <keyword>Melatonin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melatonin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

